naphthyridine-azaquinolone

specifically binds slipped-CAG DNA intermediates of expansion mutations and induces CAG repeat contractions in HD patient cells

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Gall-Duncan, Terence: 1 article (01/2022)
2.	Hasuike, Yuhei: 1 article (01/2022)
3.	Mehkary, Mustafa: 1 article (01/2022)
4.	Mochizuki, Hideki: 1 article (01/2022)
5.	Nakamori, Masayuki: 1 article (01/2022)
6.	Nakatani, Kazuhiko: 1 article (01/2022)
7.	Pearson, Christopher E: 1 article (01/2022)
8.	Tanaka, Hana: 1 article (01/2022)
9.	Tsuji, Shoji: 1 article (01/2022)

1.	Huntington Disease (Huntington's Disease) 01/01/2022 - "Previously, we characterized a small molecule, naphthyridine-azaquinolone (NA), which binds to CAG slip-out structures and induces repeat contraction in Huntington's disease mice. " 11/10/2023 - "Previously, we demonstrated that a CAG repeat-binding small molecule, naphthyridine-azaquinolone (NA), resulted in repeat contraction in mouse models of dentatorubral-pallidoluysian atrophy and Huntington's disease caused by aberrant expansion of CAG repeats. "
2.	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 11/10/2023 - "Previously, we demonstrated that a CAG repeat-binding small molecule, naphthyridine-azaquinolone (NA), resulted in repeat contraction in mouse models of dentatorubral-pallidoluysian atrophy and Huntington's disease caused by aberrant expansion of CAG repeats. "